Advanced search
Publication Cover
HIV Research & Clinical Practice Volume 23, 2022 - Issue 1
Submit an article Journal homepage
649
Views
0
CrossRef citations to date
0
Altmetric
Articles

Switching to a NRTI-free 2 drug regimen (2DR) –a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes

Malte Monin1 Bonn University Hospital, Bonn, GermanyView further author information
,
Tim Kümmerle2 Private Practice am Ebertplatz, Cologne, GermanyView further author information
,
Jochen Schneider3 Technical University of Munich, School of Medicine, University Hospital Klinikum Rechts der Isar, Munich, GermanyView further author information
,
Christiane Cordes4 Private Practice, Berlin, GermanyView further author information
,
Hans Heiken5 Private Practice Georgstrasse, Hannover, GermanyView further author information
,
Hans-Jürgen Stellbrink6 ICH Study Center, Hamburg, GermanyView further author information
,
Ivanka Krznaric7 Study Center of Infectiology Prenzlauer Berg, Berlin, GermanyView further author information
,
Stefan Scholten8 Private Practice Hohenstaufenring, Cologne, GermanyORCID Iconhttps://orcid.org/0000-0002-1863-8745View further author information
ORCID Icon,
Björn Jensen9 University Hospital Düsseldorf, Düsseldorf, GermanyView further author information
,
Heiko Jessen10 Praxis Jessen2 + Kollegen, Private Practice, Berlin, GermanyView further author information
,
Wilfried Obst11 University of Magdeburg, Magdeburg, GermanyView further author information
,
Petra Spornraft-Ragaller12 University of Dresden, Dresden, GermanyView further author information
,
Pavel Khaykin13 Private Practice, Frankfurt, GermanyView further author information
,
Annamaria Balogh14 MUC Research, Munich, GermanyView further author information
,
Eva Wolf14 MUC Research, Munich, GermanyView further author information
,
Helen Bidner15 Technical University of Munich, School of Medicine, University Hospital Klinikum Rechts der Isar, Munich Study Center, Munich, GermanyView further author information
,
Christoph D. Spinner3 Technical University of Munich, School of Medicine, University Hospital Klinikum Rechts der Isar, Munich, GermanyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3875-5367View further author information
ORCID Icon,
Christoph Boesecke1 Bonn University Hospital, Bonn, GermanyView further author information
& on behalf of the DUALIS STUDY GROUP show all
Pages 15-21 | Received 30 Sep 2021, Accepted 16 Dec 2021, Published online: 02 Mar 2022

References

  • Study Group IS, Lundgren JD, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807.
  • Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. HPTN 052-ACTG Study Team. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14(4):281–290.
  • Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
  • Achhra AC, Mwasakifwa G, Amin J, et al. Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis. Lancet Hiv. 2016;3(8):e351–e360.
  • Spinner CD, Kümmerle T, Schneider J, et al. DUALIS Study Group. Efficacy and safety of switching to dolutegravir with boosted darunavir in virologically suppressed adults with HIV-1: A randomized, open-label, multicenter, phase 3, noninferiority trial: The DUALIS Study. Open Forum Infect Dis. 2020;7:ofaa356.
  • Young J, Scherrer AU, Calmy A, Swiss HIV Cohort Study, et al. The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study. Antivir Ther. 2019;24(5):343–353. PMID: 30985290.
  • Gay CL, Neo DT, Devanathan AS, et al. Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection. AIDS. 2020;34(13):1923–1931. PMID: 32773474; PMCID: PMC7541775.
  • Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet 2018;391(10123):839–849.
  • Schneider E, Whitmore S, Glynn KM, et al. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years–United States. 2008. MMWR Recomm Rep. 2008;57(RR-10):1–12.
  • Visseren FLJ, Mach F, Smulders YM, ESC Scientific Document Group, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–3337.
  • Ribera E, Podzamczer D. Mecanismo de acción, farmacología e interacciones de dolutegravir [Mechanisms of action, pharmacology and interactions of dolutegravir. Enferm Infecc Microbiol Clin. 2015;33 (Suppl 1):2–8. Spanish. PMID: 25858605.
  • DeJesus E, Rockstroh JK, Henry K, GS-236-0103 Study Team, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379(9835):2429–2438.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.